0001127602-14-012774.txt : 20140326 0001127602-14-012774.hdr.sgml : 20140326 20140326174817 ACCESSION NUMBER: 0001127602-14-012774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140324 FILED AS OF DATE: 20140326 DATE AS OF CHANGE: 20140326 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO Co plc CENTRAL INDEX KEY: 0001585364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: TREASURY BUILDING STREET 2: LOWER GRAND CANAL STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 269-673-8451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 FORMER COMPANY: FORMER CONFORMED NAME: PERRIGO Co Ltd DATE OF NAME CHANGE: 20130828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAPA JOSEPH C CENTRAL INDEX KEY: 0001242215 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36353 FILM NUMBER: 14719636 MAIL ADDRESS: STREET 1: C/O WATSON PHARMACEUTICALS INC STREET 2: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 92880 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2014-03-24 0001585364 PERRIGO Co plc PRGO 0001242215 PAPA JOSEPH C C/O PERRIGO COMPANY 515 EASTERN AVENUE ALLEGAN MI 49010 1 1 1 President and CEO Chairman Ordinary Shares 2014-03-05 5 G 0 E 1155 0 D 95500 D Ordinary Shares 2014-03-24 4 M 0 10000 58.85 A 105500 D Ordinary Shares 2014-03-24 4 S 0 6045 157.0034 D 99455 D Ordinary Shares 2014-03-24 4 S 0 1700 157.9071 D 97755 D Ordinary Shares 2014-03-24 4 S 0 1000 159.0706 D 96755 D Ordinary Shares 2014-03-24 4 S 0 1255 159.8121 D 95500 D Employee Stock Option Right to Buy 58.82 2014-03-24 4 M 0 10000 0 D 2020-08-19 Ordinary Shares 10000 10183 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 11, 2013. This 10b5-1 sales plan will expire on the close of business November 11, 2014. The price in column 4 is a weighted average. The prices actually received ranged from $156.58 to $157.56. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. The price in column 4 is a weighted average. The prices actually received ranged from $157.59 to $158.38. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. The price in column 4 is a weighted average. The prices actually received ranged from $158.74 to $159.59. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. The price in column 4 is a weighted average. The prices actually received ranged from $159.77 to $159.95. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. Grant has graded vesting schedule. Date Exercisable will vary for each vesting tranche. /s/ Joseph C. Papa 2014-03-26